Kadeer Guzailinuer, Fu Wanrui, He Yaqi, Feng Ying, Liu Wei-Hsein, Hung Wei-Lian, Feng Haotian, Zhao Wen
Department of Nutrition, Hua Dong Hospital Affiliated to Fudan University, Shanghai, China.
Inner Mongolia Yili Industrial Group Co., Ltd., Hohhot, China.
Nutr Metab (Lond). 2023 Mar 21;20(1):16. doi: 10.1186/s12986-023-00739-y.
Studies have shown that probiotics have an effect on reducing body fat on a strain-specific and dose-response bases. The purpose of this study was to evaluate the effect of a novel probiotic strain Lacticaseibacillus paracasei K56 on body fat and metabolic biomarkers in adult individuals with obesity.
74 adult subjects with obesity (body mass index ≥ 30 kg/m, or percent body fat > 25% for men, percent body fat > 30% for women) were randomized into 5 groups and supplemented with different doses of K56 (groups VL_K56, L_K56, H_K56, and VH_K56: K56 capsules, 2 × 10 CFU/day, 2 × 10 CFU/day, 2 × 10 CFU/day, 2 × 10 CFU/day, respectively) or placebo (group Pla: placebo capsule) for 60 days. Subjects were advised to maintain their original dietary intake and physical activity. Anthropometric measurements, body composition assessment, and metabolic parameters were measured at baseline and after 60 days of intervention.
The results showed that the L_K56 group had significant decreases in percent body fat (p = 0.004), visceral fat area (p = 0.0007), total body fat mass (p = 0.018), trunk body fat mass (p = 0.003), waist circumference (p = 0.003), glycosylated hemoglobin(p = 0.002) at the end of the study compared with baseline. There were non-significant reductions in Body weight and BMI in the L_K56, H_K56, VL_K56 groups, whereas increases were observed in the placebo and VH_K56 groups compared with baseline values. In addition, K56 supplementation modulated gut microbiota characteristics and diversity indices in the L-K56 group. However, mean changes in body fat mass, visceral fat area, weight, body mass index, waist circumference and hip circumference were not significantly different between groups.
The results suggest that supplementation with different doses of Lacticaseibacillus paracasei K56 has certain effect on reducing body fat and glycosylated hemoglobin, especially at a dose of 10 CFU/day.
clinicaltrials.gov Identifier: NCT04980599.
研究表明，益生菌在菌株特异性和剂量反应基础上对减少体脂有作用。本研究的目的是评估新型益生菌副干酪乳杆菌K56对肥胖成年个体体脂和代谢生物标志物的影响。
74名肥胖成年受试者（体重指数≥30kg/m²，男性体脂百分比>25%，女性体脂百分比>30%）被随机分为5组，分别补充不同剂量的K56（VL_K56组、L_K56组、H_K56组和VH_K56组：K56胶囊，分别为2×10⁹CFU/天、2×10¹⁰CFU/天、2×10¹¹CFU/天、2×10¹²CFU/天）或安慰剂（Pla组：安慰剂胶囊），为期60天。建议受试者保持原有的饮食摄入量和身体活动。在基线和干预60天后测量人体测量指标、身体成分评估和代谢参数。
结果显示，与基线相比，L_K56组在研究结束时体脂百分比（p = 0.004）、内脏脂肪面积（p = 0.0007）、全身脂肪量（p = 0.018）、躯干体脂肪量（p = 0.003）、腰围（p = 0.003）、糖化血红蛋白（p = 0.002）均显著降低。L_K56组、H_K56组、VL_K56组体重和体重指数有不显著的降低，而安慰剂组和VH_K56组与基线值相比有所增加。此外，补充K56调节了L-K56组的肠道微生物群特征和多样性指数。然而，各组之间的体脂肪量、内脏脂肪面积、体重、体重指数、腰围和臀围的平均变化无显著差异。
结果表明，补充不同剂量的副干酪乳杆菌K56对减少体脂和糖化血红蛋白有一定作用，尤其是在剂量为10¹⁰CFU/天时。
clinicaltrials.gov标识符：NCT04980599。
